Contacts, documents and full notice history are available with a subscription.
Combined Synopsis/Solicitation NONE Expired 3 notices 3 documents

Evaluating the utility of bulk RNA transcriptomics FDA-CDER-25-128751

Solicitation FDA-CDER-25-128751 Copied Notice ID ebd4756deaef4990a822e050082eaf7f Copied HEALTH AND HUMAN SERVICES, DEPARTMENT OF — FDA OFFICE OF ACQ GRANT SVCS
SAM.gov
Posted
Jul 02, 2025
Deadline
Jul 16, 2025
Set-aside
NONE
NAICS
541714
PSC
AJ12

Summary

AI-generated · Aug 24, 2025

Provide bulk RNA sequencing/transcriptomics service to profile both coding and noncoding RNA expression in primary human hepatocytes, comparing treated versus untreated cells to identify transcriptional changes caused by the treatment. The work centers on generating bulk transcriptomics data from treated PHHs to quantify RNA expression changes and understand the treatment's impact.

Three notices contain identical requirements; no additional terms, changes, or new information are indicated.

The objective of this contract is to obtain service required to complete bulk transcriptomics of RNAs from treated and untreated primary liver hepatocytes. Transcriptomics data generated from bulk RNA sequencing will identify changes occurring for both coding and noncoding RNAs in primary human hepatocytes (PHHs) following treatment. Obtain the service required to complete bulk RNA sequencing or transcriptomics from treated primary liver hepatocytes (PHHS). Transcriptomics data generated from bulk RNA sequencing will quantify expression of both coding and noncoding RNAs in PHHs.

From Combined Synopsis/Solicitation posted on Jul 02, 2025

The objective of this contract is to obtain service required to complete bulk transcriptomics of RNAs from treated and untreated primary liver hepatocytes. Transcriptomics data generated from bulk RNA sequencing will identify changes occurring for both coding and noncoding RNAs in primary human hepatocytes (PHHs) following treatment. Obtain the service required to complete bulk RNA sequencing or transcriptomics from treated primary liver hepatocytes (PHHS). Transcriptomics data generated from bulk RNA sequencing will quantify expression of both coding and noncoding RNAs in PHHs.

From Combined Synopsis/Solicitation posted on Jul 07, 2025

The objective of this contract is to obtain service required to complete bulk transcriptomics of RNAs from treated and untreated primary liver hepatocytes. Transcriptomics data generated from bulk RNA sequencing will identify changes occurring for both coding and noncoding RNAs in primary human hepatocytes (PHHs) following treatment. Obtain the service required to complete bulk RNA sequencing or transcriptomics from treated primary liver hepatocytes (PHHS). Transcriptomics data generated from bulk RNA sequencing will quantify expression of both coding and noncoding RNAs in PHHs.

From Combined Synopsis/Solicitation posted on Jul 10, 2025

Notice history

3
  1. Combined Synopsis/Solicitation Posted Jul 02, 2025
  2. Combined Synopsis/Solicitation Posted Jul 07, 2025
    No changes from previous notice
  3. Combined Synopsis/Solicitation LATEST Posted Jul 10, 2025
    No changes from previous notice

Details

Solicitation number FDA-CDER-25-128751
Notice ID ebd4756deaef4990a822e050082eaf7f
Notice type Combined Synopsis/Solicitation
Product / Service (PSC) AJ12
NAICS 541714
Set-aside No Set aside used
Place of performance Silver Spring, Maryland
Archive date Jul 31, 2025

Award Information

Not yet awarded

Contacts

primary
Rodney D. Aytch

Email

Phone

Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF
FOOD AND DRUG ADMINISTRATION
FDA OFFICE OF ACQ GRANT SVCS

Place of Performance

Silver Spring, Maryland 20993
USA

Dates

Posted Jul 02, 2025 1 year ago
Last Updated Aug 06, 2026 2 days ago
Due Jul 16, 2025 1 year ago